Russell Investments Group Ltd. Has $1.56 Million Stock Position in Omnicell, Inc. (NASDAQ:OMCL)

Russell Investments Group Ltd. decreased its stake in Omnicell, Inc. (NASDAQ:OMCL – Get Rating) by 67.3% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 31,028 shares of the company’s stock after selling 63,845 shares during the quarter. Russell Investments Group Ltd. owned 0.07% of Omnicell worth $1,564,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. Stephens Inc. AR lifted its stake in Omnicell by 15.6% in the 3rd quarter. Stephens Inc. AR now owns 3,861 shares of the company’s stock worth $336,000 after acquiring an additional 520 shares in the last quarter. Natixis Advisors L.P. lifted its stake in Omnicell by 16.3% in the 4th quarter. Natixis Advisors L.P. now owns 16,242 shares of the company’s stock worth $819,000 after acquiring an additional 2,272 shares in the last quarter. Tributary Capital Management LLC lifted its stake in Omnicell by 69.1% in the 4th quarter. Tributary Capital Management LLC now owns 277,006 shares of the company’s stock worth $13,967,000 after acquiring an additional 113,180 shares in the last quarter. Fort Washington Investment Advisors Inc. OH lifted its stake in Omnicell by 133.9% in the 4th quarter. Fort Washington Investment Advisors Inc. OH now owns 253,033 shares of the company’s stock worth $12,758,000 after acquiring an additional 144,830 shares in the last quarter. Finally, First Light Asset Management LLC lifted its stake in Omnicell by 0.6% in the 3rd quarter. First Light Asset Management LLC now owns 349,106 shares of the company’s stock worth $30,383,000 after acquiring an additional 2,077 shares in the last quarter.

Insider Buying and Selling

In related news, Director Joanne B. Bauer sold 13,115 shares of the stock in a transaction that occurred on Tuesday, March 7th. The stock was sold at an average price of $54.24, for a total transaction of $711,357.60. Following the completion of the transaction, the director now directly owns 28,096 shares of the company’s stock, valued at $1,523,927.04. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 2.61% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. StockNews.com assumed coverage on Omnicell in a research note on Thursday, May 18th. They set a “hold” rating for the company. SVB Leerink reaffirmed a “market perform” rating on shares of Omnicell in a research note on Friday, January 27th. Piper Sandler raised their price target on Omnicell from $55.00 to $66.00 and gave the stock an “overweight” rating in a research note on Friday, January 27th. KeyCorp raised their price target on Omnicell from $65.00 to $70.00 in a research note on Wednesday, May 3rd. Finally, Benchmark raised Omnicell from a “hold” rating to a “buy” rating and set a $68.00 price target for the company in a research note on Monday, February 27th. Three research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $72.22.

Omnicell Stock Down 3.5 %

Shares of Omnicell stock opened at $72.02 on Wednesday. Omnicell, Inc. has a 1 year low of $46.11 and a 1 year high of $125.17. The business has a 50-day moving average of $61.69 and a two-hundred day moving average of $55.81. The company has a market capitalization of $3.25 billion, a P/E ratio of -180.05, a price-to-earnings-growth ratio of 10.62 and a beta of 0.90. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.06 and a quick ratio of 1.75.

Omnicell (NASDAQ:OMCL – Get Rating) last announced its quarterly earnings results on Tuesday, February 28th. The company reported $0.02 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.20. Omnicell had a positive return on equity of 5.38% and a negative net margin of 1.39%. The company had revenue of $297.67 million during the quarter, compared to the consensus estimate of $286.32 million. As a group, equities analysts predict that Omnicell, Inc. will post 0.5 EPS for the current year.

About Omnicell

(Get Rating)

Omnicell, Inc engages in the provision of medication management automation solutions and adherence tools for healthcare systems and pharmacies. Its solutions include intelligence, platform and interoperability, central pharmacy dispensing, medication adherence, population health and point of care automation.